Willem Talloen - Publications, H-index & Citations

Willem Talloen

janssen pharmaceuticals

27H指数

138论文数

2.9K被引数

收录论文 34

发表时间

Automated Spot Counting in Microbiology 微生物学中的自动点计数

IEEE-ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS

IF3.4

2023-11-01

PREAI

Lin, Chun-Pang; Duan, Yajie; Sargsyan, Davit; Cabrera, Javier; Livingston, Christine M.; Vogel, Robert; Hartman, John; Das, Mayukh; Talloen, Willem; Geys, Helena; Kanoulas, Evangelos D.; Mohanty, Surya

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2022-01-19

OAAI

Gane, Ed J.; Schwabe, Christian; Berliba, Elina; Tangkijvanich, Pisit; Jucov, Alina; Ghicavii, Nelea; Verbinnen, Thierry; Lenz, Oliver; Talloen, Willem; Kakuda, Thomas N.; Westland, Chris; Patel, Megha; Yogaratnam, Jeysen Z.; Dragone, Leonard; Van Remoortere, Pieter

JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection

GASTROENTEROLOGY

IF25.1

2020-08-01

OAAI

Zoulim, Fabien; Lenz, Oliver; Vandenbossche, Joris J.; Talloen, Willem; Verbinnen, Thierry; Moscalu, Iurie; Streinu-Cercel, Adrian; Bourgeois, Stefan; Buti, Maria; Crespo, Javier; Pascasio, Juan Manuel; Sarrazin, Christoph; Vanwolleghem, Thomas; Shukla, Umesh; Fry, John; Yogaratnam, Jeysen Z.

Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects (vol 36, pg 2450, 2019)

ADVANCES IN THERAPY

IF4

2020-03-04

OAAI

Vandenbossche, Joris; Jessner, Wolfgang; van den Boer, Maarten; Biewenga, Jeike; Berke, Jan Martin; Talloen, Willem; De Zwart, Loeckie; Snoeys, Jan; Vandyck, Koen; Fry, John; Yogaratnam, Jeysen

Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

ADVANCES IN THERAPY

IF4

2019-07-02

PREAI

Vandenbossche, Joris; Jessner, Wolfgang; van den Boer, Maarten; Biewenga, Jeike; Berke, Jan Martin; Talloen, Willem; De Zwart, Loeckie; Snoeys, Jan; Yogaratnam, Jeysen

Sequence analysis of baseline and on-treatment samples from HBV-infected chronic hepatitis B patients treated for 28 days with JNJ-56136379 monotherapy

JOURNAL OF HEPATOLOGY

IF33

2019-04-01

PREAI

Verbinnen, Thierry; Hodari, Moana; Talloen, Willem; Berke, Jan Martin; Blue, David; Yogaratnam, Jeysen; Shukla, Umesh; De Meyer, Sandra; Lenz, Oliver

JNJ-64530440, a novel capsid assembly modulator: single- and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers

JOURNAL OF HEPATOLOGY

IF33

2019-04-01

PREAI

Kakuda, Thomas; Yogaratnam, Jeysen; Westland, Christopher; Gane, Edward; Schwabe, Christian; Patel, Megha; Talloen, Willem; Lenz, Oliver; van Remoortere, Pieter

Safety, antiviral activity, and pharmacokinetics of a novel hepatitis B virus capsid assembly modulator, JNJ-56136379, in Asian and non-Asian patients with chronic hepatitis B

JOURNAL OF HEPATOLOGY

IF33

2019-04-01

PREAI

Yogaratnam, Jeysen; Zoulim, Fabien; Vandenbossche, Joris; Lenz, Oliver; Talloen, Willem; Moscalu, Iurie; Mohamed, Rosmawati; Streinu-Cercel, Adrian; Chuang, Wan-Long; Bourgeois, Stefan; Yang, Sheng-Shun; Buti, Maria; Crespo, Javier; Chen, Yi-Cheng; Manuel Pascasio, Juan; Sarrazin, Christoph; Vanwolleghem, Thomas; Shukla, Umesh; Fry, John

Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection

GASTROENTEROLOGY

IF25.1

2019-04-01

114

OAAI

Yuen, Man Fung; Gane, Edward J.; Kim, Dong Joon; Weilert, Frank; Chan, Henry Lik Yuen; Lalezari, Jacob; Hwang, Seong Gyu; Tuan Nguyen; Flores, Osvaldo; Hartman, George; Liaw, Sandy; Lenz, Oliver; Kakuda, Thomas N.; Talloen, Willem; Schwabe, Christian; Klumpp, Klaus; Brown, Nathaniel

HBcrAg decline in JNJ-56136379-treated chronic hepatitis B patients: Results of a phase 1 study

JOURNAL OF HEPATOLOGY

IF33

2019-04-01

PREAI

Lenz, Oliver; Verbinnen, Thierry; Hodari, Moana; Talloen, Willem; Vandenbossche, Joris; Shukla, Umesh; Berby, Francoise; Scholtes, Caroline; Blue, David; Yogaratnam, Jeysen; De Meyer, Sandra; Zoulim, Fabien

Safety, pharmakokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ-56136379 (JNJ-6379) in treatmentnaive chronic hepatitis B (CHB) patients without cirrhosis

JOURNAL OF HEPATOLOGY

IF33

2018-04-01

PREAI

Zoulim, F.; Yogaratnam, J. Z.; Vandenbossche, J. J.; Lenz, O.; Talloen, W.; Vistuer, C.; Moscalu, I.; Streinu-Cercel, A.; Bourgeois, S.; Buti, M.; Crespo, J.; Pascasio, J. M.; Sarrazin, C.; Vanwolleghem, T.; Blatt, L.; Fry, J.

Integrating High-Dimensional Transcriptomics and Image Analysis Tools into Early Safety Screening: Proof of Concept for a New Early Drug Development Strategy

CHEMICAL RESEARCH IN TOXICOLOGY

IF3.8

2015-09-15

OAAI

Verbist, Bie M. P.; Verheyen, Geert R.; Vervoort, Liesbet; Crabbe, Marjolein; Beerens, Dominiek; Bosmans, Cindy; Jaensch, Steffen; Osselaer, Steven; Talloen, Willem; Van den Wyngaert, Ilse; Van Hecke, Geert; Wuyts, Dirk; Van Goethem, Freddy; Gohlmann, Hinrich W. H.

High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity

LIVER INTERNATIONAL

IF5.2

2015-09-06

OAAI

Johansson, Susanne; Talloen, Willem; Tuefferd, Marianne; Darling, Jama; Fanning, Gregory; Fried, Michael W.; Aerssens, Jeroen

Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2015-08-28

OAAI

Johansson, S.; Talloen, W.; Tuefferd, M.; Darling, J. M.; Scholliers, A.; Fanning, G.; Fried, M. W.; Aerssens, J.

Identification of in vitro and in vivo disconnects using transcriptomic data 使用转录组数据鉴定体外和体内断开

BMC GENOMICS

IF3.7

2015-08-18

OAAI

Otava, Martin; Shkedy, Ziv; Talloen, Willem; Verheyen, Geert R.; Kasim, Adetayo

Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project

DRUG DISCOVERY TODAY

IF7.5

2015-05-01

OAAI

Verbist, Bie; Klambauer, Guenter; Vervoort, Liesbet; Talloen, Willem; Shkedy, Ziv; Thas, Olivier; Bender, Andreas; Goehlmann, Hinrich W. H.; Hochreiter, Sepp

Association between COMT Val158Met genotype and EEG alpha peak frequency tested in two independent cohorts

PSYCHIATRY RESEARCH

IF3.9

2014-09-01

PREAI

Veth, Cornelis P. M.; Arns, Martijn; Drinkenburg, Wilhelmus; Talloen, Willem; Peeters, Pieter J.; Gordon, Evian; Buitelaar, Jan K.

PLASMA LEVELS OF GRO ASSOCIATE WITH FIBROSIS AND PLATELET COUNTS IN HCV INFECTED PATIENTS FROM THE VIRAHEP-C COHORT

JOURNAL OF HEPATOLOGY

IF33

2014-04-01

PREAI

Johansson, S.; Talloen, W.; Tuefferd, M.; Darling, J.; Scholliers, A.; Fanning, G.; Fried, M. W.; Aerssens, J.

PREDICTION OF SEVERE CUTANEOUS REACTION DURING TRIPLE THERAPY IN HCV: VALIDATION OF A GWAS CANDIDATE GENETIC MARKER

JOURNAL OF HEPATOLOGY

IF33

2014-04-01

PREAI

Palescandolo, E.; Vijgen, L.; Talloen, W.; Colombo, M.; Mangia, A.; Wedemeyer, H.; Demasi, R.; Lonjon-Domanec, I.; Aerssens, J.

HIGH MIG (CXCL9) PLASMA LEVEL FAVORS RESPONSE TO PEGINTERFERON AND RIBAVIRIN IN HCV INFECTED PATIENTS BUT IS NOT LINKED TO DPP4 ACTIVITY

JOURNAL OF HEPATOLOGY

IF33

2014-04-01

PREAI

Johansson, S.; Talloen, W.; Tuefferd, M.; Darling, J.; Fanning, G.; Fried, M. W.; Aerssens, J.

研究方向